526 related articles for article (PubMed ID: 26965410)
1. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
3. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
7. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
[TBL] [Abstract][Full Text] [Related]
8. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
9. Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G; Masferrer E; Masferrer-Niubò M; Ferran M; Sánchez-Regaña M; Collgros H; Bordas X; Notario J; Alsina M; Gil I; Izquierdo N; Aparicio G; Mollet J; Garcia-Patos V; Pujol RM
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):56-60. PubMed ID: 24629001
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
Salvatori S; Marafini I; Monteleone G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1046-e1050. PubMed ID: 33905217
[TBL] [Abstract][Full Text] [Related]
12. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.
Martínez F; Nos P; Benlloch S; Ponce J
Inflamm Bowel Dis; 2001 Nov; 7(4):323-6. PubMed ID: 11720323
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab-induced paradoxical hidradenitis suppurativa.
Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
Poulin Y
J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
[No Abstract] [Full Text] [Related]
16. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
Shuja F; Chan CS; Rosen T
Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
Samycia M; Brassard A
J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
[TBL] [Abstract][Full Text] [Related]
18. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.
Sachdeva M; Kim P; Mufti A; Maliyar K; Sibbald C; Alavi A
J Cutan Med Surg; 2022; 26(2):176-180. PubMed ID: 34587768
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
20. Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab.
Toussirot É; Charollais R; Aubin F
Eur J Dermatol; 2016 Aug; 26(4):406-8. PubMed ID: 27099170
[No Abstract] [Full Text] [Related]
[Next] [New Search]